Affiliation:
1. Center for Tropical and Emerging Global Diseases
2. Department of Cellular Biology, University of Georgia, Athens, Georgia 30602
Abstract
ABSTRACT
A high-throughput growth assay for the protozoan parasite
Toxoplasma gondii
was developed based on a highly fluorescent transgenic parasite line. These parasites are stably transfected with a tandem yellow fluorescent protein (YFP) and are 1,000 times more fluorescent than the wild type. Parasites were inoculated in optical-bottom 384-well culture plates containing a confluent monolayer of host cells, and growth was monitored by using a fluorescence plate reader. The signal was linearly correlated with parasite numbers over a wide array. Direct comparison of the YFP growth assay with the β-galactosidase growth assay by using parasites expressing both reporters demonstrated that the assays' sensitivities were comparable but that the accuracy of the YFP assay was higher, especially at higher numbers of parasites per well. Determination of the 50%-inhibitory concentrations of three known growth-inhibiting drugs (cytochalasin D, pyrimethamine, and clindamycin) resulted in values comparable to published data. The delayed parasite death kinetics of clindamycin could be measured without modification of the assay, making this assay very versatile. Additionally, the temperature-dependent effect of pyrimethamine was assayed in both wild-type and engineered drug-resistant parasites. Lastly, the development of mycophenolic acid resistance after transfection of a resistance gene in
T. gondii
was followed. In conclusion, the YFP growth assay limits pipetting steps to a minimum, is highly versatile and amendable to automation, and should enable rapid screening of compounds to fulfill the need for more efficient and less toxic antiparasitic drugs.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference47 articles.
1. Beckers, C. J., D. S. Roos, R. G. Donald, B. J. Luft, J. C. Schwab, Y. Cao, and K. A. Joiner. 1995. Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii. Implications for the target of macrolide antibiotics. J. Clin. Investig.95:367-376.
2. Burg, J. L., D. Perelman, L. H. Kasper, P. L. Ware, and J. C. Boothroyd. 1988. Molecular analysis of the gene encoding the major surface antigen of Toxoplasma gondii. J. Immunol.141:3584-3591.
3. Caldwell, J. E., T. Heier, P. M. Wright, S. Lin, G. McCarthy, J. Szenohbradszky, M. L. Sharma, J. P. Hing, M. Schroeder, and D. I. Sessler. 2000. Temperature-dependent pharmokinetics and pharmacodynamics of vecuronium. Anesthesiology92:84-93.
4. Camps, M., G. Arrizabalaga, and J. Boothroyd. 2002. An rRNA mutation identifies the apicoplast as the target for clindamycin in Toxoplasma gondii. Mol. Microbiol.43:1309-1318.
5. Cubitt, A. B., L. A. Woollenweber, and R. Heim. 1999. Understanding structure-function relationships in the Aequorea victoria green fluorescent protein. Methods Cell Biol.58:19-30.
Cited by
176 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献